Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease is a research paper published in Gastroenterology (2020). On theSindex it has a DataRank of 5.9. It has been cited 318 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.865
From this paper's citation signal
Citation Network Contribution
5.0
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
Elan
Grant: unidentified
unidentified
California Community Foundation
Celgene
Johns Hopkins University
Schering-Plough
Teva Pharmaceutical Industries
Genentech
Johnson and Johnson
Merck
Meso Scale Diagnostics
Pfizer
Arrien Pharmaceuticals
Bristol-Myers Squibb
Gilead Sciences
Janssen Research and Development
Nestlé Health Science
Boehringer Ingelheim España
Crohn's and Colitis Foundation of America
Takeda Pharmaceutical Company
Biogen
Tillotts Pharma
Vifor Pharma
Ipsen Biopharmaceuticals
Janssen Pharmaceuticals
AstraZeneca España
Elan
National Institute of Diabetes and Digestive and Kidney Diseases
Seres Therapeutics
UCB
AbbVie
Atlantic Healthcare
Dr. Falk Pharma
Eli Lilly and Company
National Institutes of Health
Roche España
Shire
FWCI
29.47
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals